Literature DB >> 18930954

Glanzmann's thrombasthenia: an overview.

Meganathan Kannan1, Renu Saxena.   

Abstract

Glanzmann's thrombasthenia (GT) is an autosomal recessive inherited bleeding disorder due to a defect in platelet function. The hallmark of this disease is severely reduced/absent platelet aggregation in response to multiple physiological agonists. Bleeding signs in GT include epistaxis, bruising, gingival hemorrhage, gastrointestinal hemorrhage, hematuria, menorrhagia, and hemarthrosis. Homozygous or compound heterozygous mutations in the genes of GPIIb and GPIIIa lead to GT. A patient with GT, with no possible causative mutations in GPIIb and GPIIIa genes, may harbor defects in a regulatory element affecting the transcription of these 2 genes. GT occurs in high frequency in certain ethnic populations with an increased incidence of consanguinity such as in Indians, Iranians, Iraqi Jews, Palestinian and Jordanian Arabs, and French Gypsies. Carrier detection in GT is important to control the disorder in family members. Carrier detection can be done both by protein analysis and direct gene analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930954     DOI: 10.1177/1076029608326165

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  9 in total

Review 1.  Genetic analyses of integrin signaling.

Authors:  Sara A Wickström; Korana Radovanac; Reinhard Fässler
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

2.  Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia.

Authors:  Paola Giordano; Giuseppe Lassandro; Riccardina Tesse; Stefania Longo; Federica Valente; Anna Rita Cappiello; Antonio Coppola
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 3.  Recombinant activated factor VII in clinical practice: a 2014 update.

Authors:  Massimo Franchini; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

4.  Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.

Authors:  Deshun Lu; Janelle Owens; Rolf P Kreutz
Journal:  Thromb Res       Date:  2013-08-03       Impact factor: 3.944

Review 5.  [Glanzmann's thrombasthenia and pregnancy: report of a case and literature review].

Authors:  Myriam Rachad; Hikmat Chaara; Fatim zahra Fdili; Sofia Jayi; Hakimat Bouguern; Moulay Abdelilah Melhouf
Journal:  Pan Afr Med J       Date:  2011-12-21

6.  Glanzmann thrombasthenia in Pakistan: molecular analysis and identification of novel mutations.

Authors:  A Haghighi; M Borhany; A Ghazi; N Edwards; A Tabaksert; A Haghighi; N Fatima; T S Shamsi; J A Sayer
Journal:  Clin Genet       Date:  2015-07-15       Impact factor: 4.438

7.  Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia: Association with bleeding symptoms.

Authors:  Deepti Mutreja; Rahul Kumar Sharma; Abhishek Purohit; Mukul Aggarwal; Renu Saxena
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

8.  Description and Clinical Management of Patients With Glanzmann's Thrombasthenia in a University Hospital, a Referral Center Specialized in Hemostasis, in Bogotá, Colombia.

Authors:  Maria H Solano; Karen Chaves; Claudia P Casas
Journal:  Cureus       Date:  2022-06-04

9.  Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of thirty-two Turkish patients with Glanzmann thrombasthenia: a multicenter experience

Authors:  Berkay Saraymen; Sabahattin Muhtaroğlu; Mustafa Yavuz Köker; Nazan Sarper; Emine Zengin; Canan Albayrak; Davut Albayrak; Bülent Zülfikar; Başak Koç Şenol; Esma Bentli; Semih Yılmaz; Aysun Çetin; Bülent Eser; Mustafa Çetin
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.